Trade

with

SciClone Pharmaceuticals
(NASDAQ: SCLN)
AdChoices
7.58
-0.17
-2.19%
After Hours :
7.58
0.00
0.00%

Open

7.68

Previous Close

7.75

Volume (Avg)

500.41k (509.52k)

Day's Range

7.47-7.74

52Wk Range

4.24-7.91

Market Cap.

387.19M

Dividend Rate ( Yield )

-

Beta

2.13

Shares Outstanding

51.08M

P/E Ratio (EPS)

18.08 (0.42)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 127.06M

    • Net Income

    • 10.96M

    • Market Cap.

    • 387.19M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 17.73

    • PEG (Price/Earnings Growth) Ratio

    • 1.40

    • Beta

    • 2.13

    • Forward P/E

    • 20.00

    • Price/Sales

    • 3.20

    • Price/Book Value

    • 2.51

    • Price/Cash flow

    • 15.08

      • EBITDA

      • 14.17M

      • Return on Capital %

      • 12.85

      • Return on Equity %

      • 15.01

      • Return on Assets %

      • 12.85

      • Book Value/Share

      • 3.02

      • Shares Outstanding

      • 51.08M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 11.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 14.00

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 18.62

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 84.72

            • 64.72

            • Pre-Tax Margin

            • 18.83

            • 13.77

            • Net Profit Margin

            • 17.73

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 85.10

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 16.20

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 15.50

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 6.06

              • 1.52

              • Quick Ratio

              • 5.27

              • 0.87

              • Interest Coverage

              • 347.62

              • 6.77

              • Leverage Ratio

              • 1.15

              • 1.91

              • Book Value/Share

              • 3.02

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 18.59

                • 63.29

                • P/E Ratio 5-Year High

                • 18.67

                • 237.47

                • P/E Ratio 5-Year Low

                • 4.96

                • 19.71

                • Price/Sales Ratio

                • 3.30

                • 3.53

                • Price/Book Value

                • 2.59

                • 3.31

                • Price/Cash Flow Ratio

                • 15.08

                • 21.23

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 15.01

                        (18.60)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • 12.85

                        (15.20)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • 14.95

                        (18.00)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • 39.51k

                      • 27.79k

                      • Inventory Turnover

                      • 1.58

                      • 1.80

                      • Asset Turnover

                      • 0.72

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      10.43M
                      Operating Margin
                      8.21
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      15.08
                      Ownership

                      Institutional Ownership

                      62.59%

                      Top 10 Institutions

                      44.70%

                      Mutual Fund Ownership

                      27.55%

                      Float

                      88.43%

                      5% / Insider Ownership

                      5.00%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Biotechnology Discovery

                      •  

                        2,320,100

                      • 19.45

                      • 4.47

                      • Franklin Biotechnology Discovery Fund

                      •  

                        1,602,260

                      • 1.64

                      • 3.14

                      • iShares Russell 2000 (AU)

                      •  

                        807,422

                      • -1.01

                      • 1.78

                      • Vanguard Total Stock Mkt Idx

                      •  

                        694,155

                      • 0.00

                      • 1.36

                      • SEB Concept BioTech

                      •  

                        684,700

                      • -22.34

                      • 1.34

                      • iShares Nasdaq Biotechnology

                      •  

                        682,788

                      • 3.08

                      • 1.50

                      • QS Batterymarch US Sm Cp Eq Ptf

                      •  

                        495,887

                      • 0.00

                      • 0.97

                      • DFA U.S. Micro Cap Portfolio

                      •  

                        471,651

                      • 0.00

                      • 0.92

                      • Vanguard Extended Market Index Fund

                      •  

                        447,519

                      • 0.25

                      • 0.88

                      • DFA U.S. Small Cap Portfolio

                      •  

                        336,451

                      • 0.00

                      • 0.66

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Advisers, Inc.

                      •  

                        4,685,542

                      • +27.80%

                      • 9.15

                      • GL Partners Capital Management Ltd

                      •  

                        3,758,217

                      • +13.54%

                      • 7.07

                      • LSV Asset Management

                      •  

                        2,495,487

                      • -2.31%

                      • 4.87

                      • BlackRock Fund Advisors

                      •  

                        2,298,030

                      • -11.84%

                      • 4.49

                      • Dimensional Fund Advisors, Inc.

                      •  

                        2,297,884

                      • +5.97%

                      • 4.49

                      • Nantahala Capital Management, LLC

                      •  

                        1,839,628

                      • +4.40%

                      • 3.59

                      • Vanguard Group, Inc.

                      •  

                        1,457,968

                      • +0.01%

                      • 2.85

                      • Acadian Asset Management LLC

                      •  

                        1,231,135

                      • +23.72%

                      • 2.40

                      • State Street Corp

                      •  

                        975,775

                      • -1.79%

                      • 1.91

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Slow Growth

                      Style

                      Small Value

                      SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, inf...moreectious diseases and cardiovascular disorders. The Company’s primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for e...morexisting and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company’s products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.lessless

                      Key People

                      Dr. Friedhelm Blobel,PhD

                      CEO/Director/President

                      Mr. Hong Zhao

                      CEO, Divisional/CEO, Subsidiary

                      Mr. Jon S. Saxe

                      Chairman of the Board/Director

                      Wilson W. Cheung

                      CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional

                      Lan Xie

                      CFO, Divisional/Vice President, Divisional

                      • SciClone Pharmaceuticals

                      • 950 Tower Lane

                      • Foster City, CA 94404

                      • USA.Map

                      • Phone: +1 650 358-3456

                      • Fax: +1 650 358-3469

                      • sciclone.com

                      Incorporated

                      1990

                      Employees

                      570

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: